News on companion diagnostics and drug/test co-development.
AstraZeneca and Merck also announced they have filed for approval of Lynparza in patients who have mutations in more than a dozen homologous recombination repair genes.
The company said it plans to use the platform for research and development of companion diagnostics and in other oncology and precision medicine applications.
The company plans to submit a companion diagnostic version of its sequencing-based liquid biopsy test Guardant360 to various regulatory bodies.
Insight's portfolio includes a gene expression-based immuno-oncology assay for therapy response prediction.
The approval will allow clinicians to identify NSCLC patients with ROS1 fusion genes who could benefit from treatment with Rozlytrek.
